Valerie Pierce L.'s most recent trade in Ngm Biopharmaceuticals Inc was a trade of 200,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 26, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ngm Biopharmaceuticals Inc | Valerie L. Pierce | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Mar 2024 | 200,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Valerie L. Pierce | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Mar 2024 | 150,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Valerie L. Pierce | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Mar 2024 | 150,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Valerie L. Pierce | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Mar 2024 | 147,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Valerie L. Pierce | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Mar 2024 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Valerie L. Pierce | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Mar 2024 | 36,750 | 0 | - | - | Restricted Stock Unit | |
| Ngm Biopharmaceuticals Inc | Valerie L. Pierce | See Remarks | 26 Mar 2024 | 26,458 | 0 (0%) | 0% | - | Common Stock | ||
| Ngm Biopharmaceuticals Inc | Valerie Pierce L. | SVP, GC & CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.34 per share. | 16 Jan 2024 | 5,021 | 55,374 (0%) | 0% | 1.3 | 6,728 | Common Stock |
| Ngm Biopharmaceuticals Inc | Valerie L. Pierce | SVP, GC & CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Valerie L. Pierce | SVP, GC & CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 147,000 | 147,000 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Valerie L. Pierce | SVP, GC & CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 49,000 | 55,667 (0%) | 0% | 0 | Common Stock | |
| Ngm Biopharmaceuticals Inc | Valerie L. Pierce | SVP, GC & CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Valerie L. Pierce | SVP, GC & CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) |